Table 1 Changes in immune profile in patients undergoing chemotherapy
Inclusion vs 3 months (CTG) | Inclusion vs 1 year (CTG) | Time by group interaction | |||
|---|---|---|---|---|---|
Mean difference (95% CI) | p Value | Mean difference (95% CI) | p Value | p Value | |
CD4 + CD27+ | –1.64 (–7.27; 3.98) | 0.561 | 8.34 (1.53; 15.15) | 0.017 | 0.317 |
CD4 + CD28+ | –2.11 (–6.33; 2.11) | 0.321 | 5.78 (0.71; 10.85) | 0.026 | 0.018 |
CD4 + CD27 + CD28+ | –0.55 (–5.92; 4.81) | 0.836 | 8.72 (2.22; 15.22) | 0.009 | 0.328 |
CD4+/central memory | 2.65 (–0.57; 5.88) | 0.105 | 6.44 (3.4; 9.48) | <0.001 | 0.114 |
CD4 + CD27– | 0.34 (0.11; 0.57) | 0.005 | –0.26 (–0.47; –0.04) | 0.020 | <0.001 |
CD4+/TEMRA | 0.23 (0.03; 0.43) | 0.028 | –0.09 (–0.28; 0.1) | 0.343 | 0.008 |
CD8+ | 7.69 (2.62; 12.75) | 0.004 | 4.04 (–0.72; 8.8) | 0.095 | 0.116 |
CD8 + CD27+ | –4.77 (–8.8; –0.74) | 0.021 | 2.10 (–1.85; 6.06) | 0.292 | 0.008 |
CD8 + CD28+ | –5.53 (–11.3; 0.24) | 0.060 | 3.99 (–2.84; 10.83) | 0.246 | 0.011 |
CD8 + CD27 + CD28+ | –4.31 (–8.15; –0.46) | 0.029 | 3.91 (0.62; 7.2) | 0.021 | 0.004 |
CD8 + CD27-CD28– | 6.35 (1.78; 10.92) | 0.007 | –4.42 (–9.18; 0.35) | 0.068 | <0.001 |
CD8+/central memory | –0.15 (–0.35; 0.05) | 0.130 | 0.27 (0.07; 0.48) | 0.009 | 0.01 |
CD8+/naive | –0.16 (–0.40; 0.09) | 0.204 | 0.29 (0.06; 0.52) | 0.014 | 0.151 |
CD4/CD8 ratio | –0.19 (–0.32; –0.07) | 0.003 | 0.02 (–011; 0.15) | 0.757 | 0.022 |
CD4 + CD25hi FOXP3+ | –0.02 (–0.19; 0.15) | 0.857 | 0.17 (0.02; 0.33) | 0.028 | 0.185 |
CD4 + Helios+ | –0.07 (–1.14; 1.01) | 0.903 | 0.99 (0.18; 1.8) | 0.017 | 0.511 |
Lin-CD14+ | 0.20 (–0.07; 0.47) | 0.151 | 0.58 (0.33; 0.83) | <0.001 | 0.021 |
CD14 + HLA-DR– | 0.13 (0.01; 0.26) | 0.039 | 0.21 (0.08; 0.34) | 0.002 | 0.591 |
CD14 + CD124+ | 0.06 (0.01; 0.11) | 0.014 | 0.07 (0.02; 0.12) | 0.009 | 0.092 |
CD15+ | 0.44 (0.04; 0.83) | 0.031 | –0.57 (–1.15; 0.01) | 0.054 | 0.018 |